id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2012-0007,FDA,FDA-2022-E-2012,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-01-27T05:00:00Z,2025,1,2025-01-27T05:00:00Z,,2025-01-27T16:59:52Z,,0,0,090000648690058e
FDA-2022-E-2012-0006,FDA,FDA-2022-E-2012,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-02-27T05:00:00Z,2024,2,2024-02-27T05:00:00Z,,2024-02-27T15:45:51Z,,0,0,09000064863e559c
FDA-2022-E-2012-0005,FDA,FDA-2022-E-2012,Letter to U. S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2023-12-29T05:00:00Z,2023,12,2023-12-29T05:00:00Z,,2023-12-29T14:12:29Z,,0,0,090000648636569b
FDA-2022-E-2012-0004,FDA,FDA-2022-E-2012,Determination of Regulatory Review Period for Purposes of Patent Extension; LYBALV,Notice,Determinations,2023-12-21T05:00:00Z,2023,12,2023-12-21T05:00:00Z,2024-02-21T04:59:59Z,2023-12-21T15:40:37Z,2023-28094,0,0,090000648634e3d6
FDA-2022-E-2012-0003,FDA,FDA-2022-E-2012,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-09-28T04:00:00Z,2022,9,2022-09-28T04:00:00Z,,2022-09-28T20:29:19Z,,0,0,090000648537ac35
FDA-2022-E-2012-0001,FDA,FDA-2022-E-2012,Letter from U S Patent and Trademark Office,Other,Letter(s),2022-08-25T04:00:00Z,2022,8,2022-08-25T04:00:00Z,,2022-08-25T14:01:30Z,,0,0,0900006485273903
FDA-2022-E-2012-0002,FDA,FDA-2022-E-2012,"Patent Term Extension Application for LYBALVI® Patent No 10,300,054",Other,Application,2022-08-25T04:00:00Z,2022,8,2022-08-25T04:00:00Z,,2022-08-25T14:04:42Z,,0,0,0900006485273baa